# Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

> **NCT01281917** · PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 40 (actual)

## Conditions studied

- Non-Hodgkins Lymphoma

## Interventions

- **DRUG:** Velcade
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01281917
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2013-10
- **Final completion:** 2014-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-12-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01281917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01281917, "Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01281917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*